Skip to main content
. 2014 Jul 23;25(10):1941–1948. doi: 10.1093/annonc/mdu269

Figure 4.

Figure 4.

Kaplan–Meier curves for (A) progression-free survival, and (B) overall survival by KRAS gene mutation (KRAS MT) status. Van (vandetanib), Doc (docetaxel), Pbo (placebo), mo (months), HR (hazard ratio), CI (confidence interval). HR <1.0 favors vandetanib + docetaxel versus placebo + docetaxel.